In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CAT, Human Genome Sciences in $67mm antibody collaboration

Executive Summary

In exchange for use of Cambridge Antibody Technology's fully human antibodies and antibody technology, Human Genome Sciences will pay (uf)$54.9mm up front, which gives them a 6% stake in the company, purchasing 1.67mm CAT shares at about $33 (UK20.75) each (a (pr)20% premium to market price). In addition, HGS will pay (uf)$12mm up front in licensing and three years worth of research support, plus milestones and sales royalties.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies